Influence of dasatinib treatment on body height in children with acute myeloid leukemia.
- Author:
Fang-Yuan ZHENG
1
;
Ai-Dong LU
;
Le-Ping ZHANG
;
Ying-Xi ZUO
;
Yue-Ping JIA
;
Jun WU
Author Information
1. Department of Pediatrics, Peking University People's Hospital, Beijing 100044, China. zhangleping@pkuph.edu.cn.
- Publication Type:Journal Article
- MeSH:
Adolescent;
Body Height;
Child;
Dasatinib;
therapeutic use;
Growth Disorders;
Humans;
Leukemia, Myeloid, Acute;
drug therapy;
Retrospective Studies
- From:
Chinese Journal of Contemporary Pediatrics
2020;22(1):47-52
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To study the influence of dasatinib treatment on body height in children with acute myeloid leukemia (AML).
METHODS:A retrospective analysis was performed for the clinical data of 86 AML children aged <17 years. According to the treatment regimen, these children were divided into a conventional chemotherapy group and a dasatinib chemotherapy group. The 57 children in the conventional chemotherapy group were given conventional chemotherapy drugs without tyrosine kinase inhibitor, and the 29 children in the dasatinib chemotherapy group were given conventional chemotherapy drugs and dasatinib. The two groups were compared in terms of height standard deviation score (HtSDS) at the beginning of treatment and after treatment, as well as the change in HtSDS after 1 and 2 years of treatment.
RESULTS:There was no significant difference in HtSDS between the conventional and dasatinib chemotherapy groups before treatment. Within the first two years of treatment, the dasatinib chemotherapy group had a similar change trend of HtSDS as the conventional chemotherapy group. Four children in the dasatinib chemotherapy group reached the final adult height during follow-up, which was significantly lower than the target height (P=0.044). In the conventional chemotherapy group, there was no significant difference between final adult height and target height. In the dasatinib chemotherapy group, the children in adolescence had a significant change in HtSDS after treatment (P=0.032).
CONCLUSIONS:Dasatinib treatment may affect the final height of children with AML, and the use of dasatinib after the beginning of adolescence may lead to growth disorder, but dasatinib treatment has little effect on body height in the short-term treatment.
